By Editorial Team 
The healthcare AI field is a minefield, where a great clinical story often runs straight into a wall of commercial reality. If you’re a health tech analyst or a payer reviewer, your job is to tell the difference between a sustainable business and fleeting hype, and that means looking way past the glossy trial readouts. The latest randomized clinical trial from Click Therapeutics, for a prescription software to treat negative symptoms of schizophrenia, is a perfect case study. It presents credible evidence for a notoriously tough condition, but it also shows up right after the spectacular financial collapse of Pear Therapeutics, a pioneer in the exact same product class.
The Clinical Promise: Click Therapeutics and Schizophrenia
Click Therapeutics works on software-as-a-treatment, trying to bridge biology and tech. Their recent randomized trial for a prescription software targeting negative symptoms of schizophrenia is a big deal Click Therapeutics trial publication. And it should be. Symptoms like anhedonia, avolition, and social withdrawal are devastating for patients and notoriously hard to treat with drugs. Publishing an RCT for this is a huge step toward clinical validation and gives patients some real hope. The Phase III CONVOKE study enrolled 457 adults across 66 U.S. sites, randomizing 227 to their product Motivista (formerly CT-155) and 230 to a digital control. The results showed a Cohen’s D effect size of -0.36 (p=0.0003), which translated to a 6.8-point improvement in negative symptoms on the CAINS-MAP scale at 16 weeks, a 62% relative improvement over the 4.2 points seen in the control group. Of course, the revenue figures for this program aren’t public. But for an analyst, these clinical details are the baseline for figuring out potential market impact. On its own, the clinical evidence looks like a solid step forward for an unmet medical need.
The Shadow of Collapse: The Pear Therapeutics Bankruptcy Entry
You can’t get excited about new clinical data for prescription software without looking at the wreckage in the category. The bankruptcy of Pear Therapeutics just looms over everything Pear Therapeutics bankruptcy filing. Pear was the first mover, the company that blazed the trail through the tough regulatory process to get its digital therapeutics to market. And even with those regulatory wins, the company imploded. The forensic fact here is the financial collapse documented in the Pear Therapeutics Bankruptcy entry: after filing for Chapter 11 in April 2023, its assets were auctioned off for a mere $6.05 million. At the time, Pear had $5.7 million in cash but also over $500 million in other assets (mostly tax losses and internal IOUs) against $130 million in liabilities. Regulatory clearance and clinical efficacy are table stakes, but they don’t guarantee a sustainable business. Pear’s failure exposes the biggest risk in healthcare AI: the chasm between having strong evidence and finding a viable revenue stream with payer coverage that ensures you can last. When the first company to get a product cleared in a new category goes under, you have to ask what “success” in health tech even means.
The Evidence-Sustainability Gap: A Healthcare AI Risk
Putting Click’s new trial data next to Pear’s bankruptcy filing shows you the deep gap between proving a product works and proving it can survive as a business. Trial readouts, by design, don’t capture this risk. A good RCT answers one question: does the intervention work? It tells you nothing about whether payers will cover it, if the market is ready for it, or if the business model can actually support the company long enough to matter. For any health tech analyst or payer reviewer, this is where the real work begins. The Pear experience proves that getting a 510(k) clearance or De Novo classification for a pure software-as-a-medical-device (SaMD) product is just the beginning of the battle. Without a clear reimbursement pathway and consistent payer buy-in, even a clinically effective product can die on the vine. This isn’t a technical problem of algorithmic drift or quality management systems. It’s a fundamental breakdown in the commercial path for a new class of medicine. The fact that these reports carry no vendor performance or guarantee figures just means you have to dig even deeper than the technical specs.
What a Careful Reader Should Watch
So, when you look at Click Therapeutics’ promising schizophrenia trial, you have to read between the lines. What does the record not show? The company did get FDA 510(k) clearance for Motivista (formerly CT-155) on July 30, 2026, as the first authorized treatment for negative symptoms of schizophrenia. And in April 2026, Click raised a $50 million Series D led by Boehringer Ingelheim Venture Fund, with more undisclosed funding to back Motivista’s launch. But here’s a telling detail: Boehringer Ingelheim transferred the full commercial and marketing rights for the product back to Click Therapeutics. Now, set that against the Pear Therapeutics Bankruptcy entry. It provides a stark, category-level fact: a cleared pioneer in this exact same class of prescription software couldn’t make a go of it. Does this mean Click is doomed to the same fate? Not necessarily, and there’s no stated business link between them. But the precedent is undeniable. It shifts the conversation from a simple trial announcement to a much tougher question: what does this new evidence mean for a category whose first major company went bankrupt? Analysts and payers need to start asking about the unstated. Is there a clear path to revenue? What’s the real strategy for getting broad payer coverage, not just a few pilot programs? What are the projections for sticking around beyond the initial launch excitement? These are the questions that get past the efficacy data and into whether a company can actually turn a clinical win into a lasting business that helps patients. Pear’s story is a blunt reminder that for healthcare AI, you need category-level forensics, not just trial optimism, to see the real risks. FDA guidance on digital health reimbursement
Frequently Asked Questions
What is the primary clinical evidence supporting Click Therapeutics’ schizophrenia treatment?
Click Therapeutics’ recent randomized clinical trial, the Phase III CONVOKE study, demonstrated a Cohen’s D effect size of -0.36, reflecting a 6.8-point improvement in negative symptom severity as measured by CAINS-MAP at 16 weeks, compared to 4.2 points in the digital control arm. This represents a 62% relative improvement for their prescription software-based treatment for negative symptoms of schizophrenia.
How does the collapse of Pear Therapeutics impact the evaluation of new prescription software treatments like Click Therapeutics’?
The collapse of Pear Therapeutics, a pioneer in the prescription software treatment class, highlights a significant gap between clinical efficacy and business sustainability. It serves as a stark reminder that regulatory clearance and positive clinical trial results do not automatically guarantee a viable revenue path, payer coverage, or long-term durability for these types of health technologies.
What critical factors, beyond clinical trial results, should be considered when assessing the long-term viability of Click Therapeutics’ product?
Beyond clinical trial results, it is crucial to consider whether the market is ready, if payers will cover the treatment, and if the business model is robust enough to sustain operations. The absence of a clear reimbursement pathway and consistent payer coverage can render even clinically effective solutions unsustainable, as demonstrated by Pear Therapeutics’ experience.
Has Click Therapeutics received regulatory clearance for its schizophrenia treatment, Motivista?
Yes, Click Therapeutics received FDA 510(k) clearance for Motivista (formerly CT-155) on July 30, 2026. This makes it the first FDA-authorized treatment for negative symptoms of schizophrenia.
